Background
Ovarian cancer (OC) is occult, 70% of OC patients are advanced at first
visit, the recurrence rate is 70% within 3 years after initial
treatment, and the 5-year survival rate of advanced OC patients is only
about 40%[1] .The main reason is that
patients are prone to early distant metastasis, and at the same time,
they are prone to resistance to platinum drugs in the later stage of
chemotherapy[2] .Epithelial ovarian cancer
(EOC) has the highest mortality rate among gynecological
tumors[3] ,High-grade serous
carcinoma(High-grade serous carcinoma,HGSC)is the most common histology
in EOC.Subtype.Despite significant advances in the treatment of
epithelial ovarian cancer in the past few decades, recurrent ovarian
cancer remains a fatal disease, often controlled by combined treatment
with surgery and chemotherapy[4] .Because
the clinical needs of these patients are arguably the greatest, our
focus is on treating advanced disease. Through continued progress, we
hope that ovarian cancer will transition from a highly fatal disease to
a chronic but treatable disease and gradually become a curable disease.
Aidi injection is mainly composed of astragalus root, ginseng,
acanthopanax root, etc.In ovarian cancer, it mainly lies in inhibiting
tumor angiogenesis by down-regulating vascular endothelial growth
factor[5] , reduce the expression of
proteins encoded by carcinogenic active genes, thereby producing
anti-tumor effects[6] .The compound
matrine injection is mainly composed of matrine and oxymatrine (also
known as matrine). This kind of alkaloid has many pharmacological
activities, among which the most significant one is antitumor
activity[7] .Its main effects include
inhibition of cell proliferation, induction of apoptosis and autophagy,
inhibition of cell migration and invasion, inhibition of tumor
angiogenesis, reversal of multidrug resistance of tumor cells and
regulation of immunity[8-13] .
Although the use of Aidi combined with Sophora flavescens as a treatment
for ovarian cancer is not fully understood, it offers promise as a
complementary therapy. Here, we present a study of patients with
advanced recurrent ovarian cancer treated with Aidi combined with
Sophora flavescens for prevention of recurrence and metastasis. This
treatment resulted in 86 months of progression-free survival (PFS) after
chemotherapy for ovarian cancer, complete remission after palliative
chemotherapy for recurrence and metastasis, The median progression-free
survival (PFS) of 9.2 months was well
exceeded[14] .